Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies

Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor evaluated in multiple B-cell malignancy studies. We constructed a pooled safety analysis to better understand zanubrutinib-associated treatment-emergent adverse events (TEAEs) and identify treatment-limiting toxicities. Data were poo...

Descripción completa

Detalles Bibliográficos
Autores principales: Tam, Constantine S., Dimopoulos, Meletios, Garcia-Sanz, Ramon, Trotman, Judith, Opat, Stephen, Roberts, Andrew W., Owen, Roger, Song, Yuqin, Xu, Wei, Zhu, Jun, Li, Jianyong, Qiu, Lugui, D’Sa, Shirley, Jurczak, Wojciech, Cull, Gavin, Marlton, Paula, Gottlieb, David, Munoz, Javier, Phillips, Tycel, Du, Chenmu, Ji, Meng, Zhou, Lei, Guo, Haiyi, Zhu, Hongjie, Chan, Wai Y., Cohen, Aileen, Novotny, William, Huang, Jane, Tedeschi, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864647/
https://www.ncbi.nlm.nih.gov/pubmed/34724705
http://dx.doi.org/10.1182/bloodadvances.2021005621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864647/
https://www.ncbi.nlm.nih.gov/pubmed/34724705
http://dx.doi.org/10.1182/bloodadvances.2021005621

Ejemplares similares